Pelitinib
Pelitinib structure
|
Common Name | Pelitinib | ||
|---|---|---|---|---|
| CAS Number | 257933-82-7 | Molecular Weight | 467.923 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 655.5±55.0 °C at 760 mmHg | |
| Molecular Formula | C24H23ClFN5O2 | Melting Point | 173-178ºC | |
| MSDS | USA | Flash Point | 350.2±31.5 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Pathol. Oncol. Res. 21 , 957-68, (2015) BRAF and NRAS are the two most frequent oncogenic driver mutations in melanoma and are pivotal components of both the EGF and FGF signaling network. Accordingly, we investigated the effect of BRAF and NRAS oncogenic mutation on the response to the stimulation... |
|
|
Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
Br. J. Pharmacol. 172 , 4089-106, (2015) Pelitinib is a potent irreversible EGFR TK inhibitor currently in clinical trials for the treatment of lung cancer. Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance treatment outcome. In this study, we investigated the... |
|
|
A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.
Cancer Biol. Ther. 14 , 95-9, (2013) Current therapies for Renal Cell Carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulati... |